Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + docetaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Adebrelimab + docetaxel + cisplatin is a combination chemo-immunotherapy regimen being investigated for the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Adebrelimab is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors to restore anti-tumor T-cell activity. The TP regimen consists of docetaxel, a microtubule inhibitor that promotes tubulin assembly and inhibits depolymerization, and cisplatin, a platinum-based agent that forms DNA cross-links to inhibit DNA synthesis. This combination aims to leverage the cytotoxic effects of chemotherapy with the immune-potentiating effects of checkpoint inhibition to improve pathological response rates before surgery or radiotherapy.
- Brand names
- Airuika
- Other names
- Adebrelimab + TP regimenAdebrelimab + Docetaxel + Cisplatin
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on adebrelimab + docetaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + docetaxel + cisplatin.